Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Garber

Showing results (441-450 of 605) with videos related to

Pageof 61
Sort By:
ACS Synthetic Biology|December 17, 2019
Identification, Characterization, and Application of a Highly Sensitive Lactam Biosensor from <i>Pseudomonas putida</i>Mitchell G Thompson, Allison N Pearson, Jesus F Barajas, et al.
JCO Precision Oncology|December 7, 2023
Endometrial Cancer Risk Among Germline <i>BRCA1</i>/<i>2</i> Pathogenic Variant Carriers: Review of Our Current Understanding and Next StepsKimia Sorouri, Filipa Lynce, Colleen M Feltmate, et al.
Cancer|September 5, 2014
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panelNadine Tung, Chiara Battelli, Brian Allen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2004
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck, Tara Friebel, Henry T Lynch, et al.
Cancer Research|October 28, 1999
Germ-line msh6 mutations in colorectal cancer familiesR D Kolodner, J D Tytell, J L Schmeits, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapyHarold J Burstein, Yu-Hui Chen, Leroy M Parker, et al.
Critical Care Medicine|September 23, 2003
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and resultsJean-François Dhainaut, Pierre-François Laterre, Steven P LaRosa, et al.
Breast Cancer Research and Treatment|January 23, 2019
Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at riskAnna Weiss, Samantha Grossmith, Danielle Cutts, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 15, 2001
Diversity of gene expression in adenocarcinoma of the lungM E Garber, O G Troyanskaya, K Schluens, et al.
Future Oncology (London, England)|October 15, 2016
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationaleSteven J Isakoff, Shannon Puhalla, Susan M Domchek, et al.
Pageof 61

Showing results (441-450 of 605) with videos related to

Sort By:
Pageof 61
ACS Synthetic Biology|December 17, 2019
Identification, Characterization, and Application of a Highly Sensitive Lactam Biosensor from <i>Pseudomonas putida</i>Mitchell G Thompson, Allison N Pearson, Jesus F Barajas, et al.
JCO Precision Oncology|December 7, 2023
Endometrial Cancer Risk Among Germline <i>BRCA1</i>/<i>2</i> Pathogenic Variant Carriers: Review of Our Current Understanding and Next StepsKimia Sorouri, Filipa Lynce, Colleen M Feltmate, et al.
Cancer|September 5, 2014
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panelNadine Tung, Chiara Battelli, Brian Allen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2004
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study GroupTimothy R Rebbeck, Tara Friebel, Henry T Lynch, et al.
Cancer Research|October 28, 1999
Germ-line msh6 mutations in colorectal cancer familiesR D Kolodner, J D Tytell, J L Schmeits, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapyHarold J Burstein, Yu-Hui Chen, Leroy M Parker, et al.
Critical Care Medicine|September 23, 2003
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and resultsJean-François Dhainaut, Pierre-François Laterre, Steven P LaRosa, et al.
Breast Cancer Research and Treatment|January 23, 2019
Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at riskAnna Weiss, Samantha Grossmith, Danielle Cutts, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 15, 2001
Diversity of gene expression in adenocarcinoma of the lungM E Garber, O G Troyanskaya, K Schluens, et al.
Future Oncology (London, England)|October 15, 2016
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationaleSteven J Isakoff, Shannon Puhalla, Susan M Domchek, et al.
Pageof 61